Hepatocellular Carcinoma

HCC usually develops in cirrhosis of any cause, but it can occur without cirrhosis, particularly in chronic hepatitis B virus infection and metabolic dysfunction-associated steatotic liver disease. Continue structured surveillance in patients with hepatitis C virus-related cirrhosis after virologic cure. BMJ+2BMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best Practice USBMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best PracticeNEJMUpdated Practice Guidance on Diagnosis and Management of Hepatocellular Carcinoma | NEJM Clinician

Use liver ultrasound with alpha-fetoprotein (AFP) at 6-month intervals for primary surveillance in at-risk patients. CT and MRI are diagnostic and staging tests rather than routine first-line surveillance modalities. BMJ+1BMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best Practice USNEJMUpdated Practice Guidance on Diagnosis and Management of Hepatocellular Carcinoma | NEJM Clinician

Do not interpret a normal AFP as exclusion of HCC. AFP-nonproducing HCC occurs, and AFP status may add prognostic and transplant-selection information only when integrated with radiologic and clinical assessment. JAMAJAMAHepatocellular Carcinomas That Do Not Produce α- ...

When surveillance identifies a focal lesion or the clinical picture raises concern for HCC, proceed to dedicated multiphasic CT or multiphasic MRI rather than repeating routine ultrasound. Ultrasound performance is operator dependent and can be limited by inadequate liver visualization, making cross-sectional imaging especially important when surveillance quality is poor or a lesion is suspected. ScienceDirect+1ScienceDirectThe Diagnosis and Staging of Hepatocellular Carcinoma: A Review of Current Practices - ScienceDirectWileyDiagnosis, Staging, and Management of Hepatocellular ...

Use either multiphasic CT or multiphasic MRI for diagnostic evaluation because AASLD guidance recognizes similar diagnostic performance. Interpret studies with LI-RADS, which standardizes reporting and is applicable to multiphasic CT or MRI in patients with cirrhosis. Wiley+2WileyDiagnostic Criteria and li- raDs for Hepatocellular CarcinomaWileySurveillance and Diagnosis of Hepatocellular CarcinomaWileyDiagnosis, Staging, and Management of Hepatocellular ...

Do not extrapolate LI-RADS-based noninvasive diagnostic conclusions to patients outside its intended high-risk population. In noncirrhotic patients, atypical lesions, and cases in which imaging cannot establish the diagnosis or would alter treatment selection, obtain multidisciplinary review and consider tumor biopsy. Updated EASL guidance emphasizes an expanding role for tumor biopsy in selected scenarios. Wiley+1WileyDiagnostic Criteria and li- raDs for Hepatocellular Carcinomaeasl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.

Stage beyond lesion size and number. Determine intrahepatic tumor distribution, macrovascular invasion, extrahepatic spread, liver function, portal-hypertension consequences, performance status, and feasibility of curative therapy. BCLC stage links prognosis and treatment strategy from very early/early disease through intermediate, advanced, and end-stage disease. BMJ+1BMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best PracticeScienceDirectEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Treat portal-vein tumor thrombus as an advanced, high-complexity phenotype requiring careful multidisciplinary selection. Evidence supporting TACE plus durvalumab and bevacizumab or lenvatinib plus pembrolizumab in phase III trials does not directly establish benefit in portal-vein tumor thrombus because those trials excluded such patients. NatureNatureLocoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis | Scientific Reports

For very early or early HCC with good liver function, evaluate surgical resection first when adequate liver reserve and operative candidacy permit. BCLC stage 0-A identifies patients who may be surgical candidates, while selection must still account for hepatic function and postoperative decompensation risk. BMJBMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best Practice

Evaluate liver transplantation when it can provide tumor control while replacing a cirrhotic liver at risk for decompensation and future tumors. Downstage selected tumors to within Milan criteria before wait-list inclusion; guideline-based reviews describe a 6-month interval after successful downstaging before listing. ScienceDirect+1ScienceDirectReview Article Hepatocellular carcinomaeasl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.

Use percutaneous local ablation as a curative alternative for small tumors when resection is unsuitable. Local ablation is an acceptable alternative to resection for HCC smaller than 3 cm in Child-Pugh A or B disease, whereas resection is preferred over ablation for resectable 3- to 5-cm tumors in Child-Pugh A liver function. PubMedPubMedHong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma - PMC

Do not treat procedure selection as interchangeable. Resection may be favored for a resectable lesion in well-compensated liver disease, while transplantation addresses both tumor and liver failure risk; ablation may preserve parenchyma when surgical reserve is limited. Newer guidance also supports minimally invasive surgical approaches in selected patients. easl eu+1easl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.PubMedHong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma - PMC

For unresectable large or multifocal HCC without vascular invasion or extrahepatic spread and with satisfactory Child-Pugh A or B liver function, TACE is an established first-line locoregional option. Its mechanism combines selective arterial occlusion with high local chemotherapy delivery. Nature+1NatureLocoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis | Scientific ReportsPubMedHong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma - PMC

Consider TARE and external-beam approaches such as SBRT when anatomy, tumor distribution, prior treatment, or embolization tolerance makes them preferable. Comparative safety data suggest TARE has the lowest complication rate among evaluated arterial approaches, while drug-eluting bead TACE had a better side-effect profile than conventional TACE except for fatigue. Oxford AcademicOxford AcademicRole of interventional oncology in hepatocellular carcinoma ...

Use SBRT as a selected alternative or complement to established liver-directed modalities, not merely as salvage by default. Contemporary guidance recognizes expanding roles for internal and external radiation approaches and for transitions among surgery, locoregional therapy, and systemic treatment. easl eueasl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.

Do not persist with repeated locoregional procedures when disease pattern, liver function, or treatment response indicates a shift to systemic treatment. The treatment plan should be reassessed after each modality based on viable tumor, new vascular invasion or spread, hepatic reserve, and candidacy for curative conversion or transplantation. easl eueasl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.

For advanced-stage HCC, use a multidisciplinary systemic-therapy strategy informed by performance status, liver function, macrovascular invasion, extrahepatic spread, prior liver-directed therapy, and bleeding or procedural risks. Current guidance highlights combination immunotherapies as a major component of contemporary advanced-stage management. BMJ+2BMJHepatocellular carcinoma - Symptoms, diagnosis and treatment | BMJ Best Practice USeasl euNew EASL Clinical Practice Guidelines on Hepatocellular Carcinoma - EASL-The Home of Hepatology.ASCOManagement of Advanced Hepatocellular Carcinoma

Avoid applying trial results to portal-vein tumor thrombus without checking eligibility. EMERALD-1 reported progression-free survival benefit with TACE plus durvalumab and bevacizumab, and LEAP-012 reported similar benefit with TACE plus lenvatinib and pembrolizumab, but both trials excluded portal-vein tumor thrombus. NatureNatureLocoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis | Scientific Reports

For HCC with portal-vein tumor thrombus, recognize that multimodal regimens remain unsettled. A 2025 meta-analysis found better tumor response and survival with locoregional therapy added to targeted therapy plus immunotherapy than with targeted therapy plus immunotherapy alone; HAIC-based approaches were associated with better overall survival and radiotherapy-based approaches with better progression-free survival than TACE-based approaches. These findings require individualized interpretation because randomized multicenter trials are still needed to define optimal regimen and sequencing. NatureNatureLocoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis | Scientific Reports

After any treatment, reassess radiographic response, intrahepatic progression, vascular invasion, extrahepatic disease, liver function, functional status, and candidacy for the next treatment line. A radiologic complete response after combined locoregional therapy and immunotherapy can be durable in selected unresectable HCC cohorts, but observation after complete response should be applied within structured oncologic follow-up rather than presumed cure. JAMAJAMAComplete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma